State Management of the Sphere of Circulation of Medicines in the Context of the COVID-19 Pandemic

This article analyzes the state management of the sphere of circulation of medicines in the Republic of Kazakhstan in the context of the COVID-19 pandemic, and analyzes the reasons for the shortage of medicines in the specified period. The authors conducted a sociological survey, which made it possible to identify the main problems faced by the population during the COVID-19 pandemic. All major players in the pharmaceutical market of the Republic of Kazakhstan are analyzed. The activity of «SK-Pharmacy» during the COVID-19 pandemic was considered, and measures aimed at eliminating ineffective management identified in the work of a single distributor of medicines were analyzed. The measures of the state to reduce prices for essential medicines during a pandemic are considered. Based on domestic and foreign experience, an analysis of external reference pricing for medicines was carried out. The expenditures of the population on health care, including on medicines, were considered. The study resulted in the proposed measures to improve public administration in the sphere of drug circulation in the Republic of Kazakhstan. It is concluded that the state needs to take several measures in the field of drug circulation to prevent a possible shortage of pharmaceuticals and contain drug prices during future pandemics. It is necessary to increase funding for the health care system, including for medicines, without shifting the financial burden on the population and employers. It is necessary to build an effective system of pricing for medicines, which would consider the peculiarities of the global and Kazakhstani pharmaceutical market.

1. Bochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., Duborija-Kovacevic, N., Fürst, J., Gaga, M., Gailīte, E., Gulbinovič, J., Gürpınar, E. U., Hankó, B., Hargaden, V., Hotvedt, T. A., Hoxha, I., & Godman, B. (2018). Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Frontiers in pharmacology, 8, 942. https://doi.org/10.3389/fphar.2017.00942

2. Acosta, A., Vanegas, E. P., Rovira, J., Godman, B., & Bochenek, T. (2019). Medicine Shortages: Gaps Between Countries and Global Perspectives. Frontiers in pharmacology, 10, 763. https://doi.org/10.3389/fphar.2019.00763

3. Badreldin, H. A., & Atallah, B. (2021). Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies. Research in social & administrative pharmacy: RSAP, 17(1), 1946-1949. https://doi.org/10.1016/j.sapharm.2020.05.017

4. Vogler, S., & Fischer, S. (2020). How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health policy, 124(12), 1287-1296. https://doi.org/10.1016/j.healthpol.2020.09.001

5. Shuman, A. G., Fox, E., & Unguru, Y. (2020). Preparing for COVID-19-related Drug Shortages. Annals of the American Thoracic Society, 17(8), 928-931. https://doi.org/10.1513/AnnalsATS.202004-362VP

6. Pisani, E., Nistor, A. L., Hasnida, A., Parmaksiz, K., Xu, J., & Kok, M. O. (2019). Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome open research, 4, 70. https://doi.org/10.12688/wellcomeopenres.15236.1

7. Zordinova, K. A. (2015). Problema fal’sificirovannyh i substandartnyh lekarstvennyh sredstv v mire i v Kazahstane. Vestnik Kazahskogo nacional’nogo medicinskogo universiteta, 1, 459-464.

8. Toropygin, A. V. (2018). Politiko-pravovye aspekty formirovanija regional’nogo rynka lekarstv Evrazijskogo jekonomicheskogo sojuza. Evrazijskaja integracija: jekonomika, pravo, politika, 2(24), 98-107.

9. Toregozhina, M. B. (2019). Konkurentosposobnost’ himiko-farmacevticheskoj otrasli Respubliki Kazahstan v ramkah EAJeS. Statistika, uchet i audit, 3(74), 223-227.

10. Marceva, T. G., Voblaja, I. N., Sejfieva, E. N. (2019). Osobennosti regulirovanija farmacevticheskogo rynka Evrazijskogo jekonomicheskogo sojuza.Problemy social’noj gigieny, zdravoohranenija i istorii mediciny, 27 (5), 841-846. https://doi.org/10.32687/0869-866X-2019-27-5-841-846

11. Bortnikova, A. P. (2018). Formirovanie obshhego farmacevticheskogo rynka EAJeS: problemy i ih reshenija. Evrazijskij juridicheskij zhurnal, 8(123), 19-21.

12. Djusembinova, G. A., Iskakova, B. Z., Serikbaeva, Je. A., Doshmanova. S. D. (2020). Farmacevticheskij rynok Kazahstana v uslovijah vnedrjaemoj politiki normativnogo pravovogo regulirovanija. Farmacija Kazahstana, 3, 45-48.

13. Dzhilissen, Je., Malligan, K., Tottman, S., Troen. P. (2020). Gibkoe upravlenie zapasami: strahovanie postavok lekarstvennyh sredstv. Remedium. Zhurnal o rossijskom rynke lekarstv i medicinskoj tehniki. 11(12), 4-17. https://doi.org/10.21518/1561-5936-2020-11-12-4-17

14. Akimov, A. V. (2021). Rol’ VOZ v bor’be s COVID-19. Itogi pervogo goda. Mezhdunarodnaja zhizn’, 5, 16-31.

15. Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J., Sidhu, P., Atallah, B., El-Lababidi, R., & Al-Qahtani, M. (2021). COVID-19: breaking down a global health crisis. Annals of clinical microbiology and antimicrobials, 20(1), 35. https://doi.org/10.1186/s12941-021-00438-7

16. Haug, N., Geyrhofer, L., Londei, A. et al. (2020). Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 4, 1303-1312. https://doi.org/10.1038/s41562-020-01009-0

17. Brauner, J. M., Mindermann, S., Sharma, M., Johnston, D., Salvatier, J., Gavenčiak, T., Stephenson, A. B., Leech, G., Altman, G., Mikulik, V., Norman, A. J., Monrad, J.T., Besiroglu, T., Ge, H., Hartwick, M.A., Teh, Y. W., Chindelevitch, L., Gal, Y., & Kulveit, J. (2021). Inferring the effectiveness of government interventions against COVID-19. Science, 371(6531):eabd9338. https://doi.org/10.1126/science.abd9338

18. Shah, S., Ray, B., Holy, C., Sakthivel, M., Elangovanraaj, N., Krishnan, D., Gupta, S., Trivedi, P., Devulapally, M., Mohapatra, A., & Coplan, P. (2020). IN3 Impact of Government Measures on COVID-19 Incidence of Reported New Cases: An Analysis of 9 Countries. Value in Health, 23, S403. https://doi.org/10.1016/j.jval.2020.08.038

19. Tereshhenko, A. P. (2020). Obespechenie lekarstvennoj nezavisimosti kak faktor jekonomicheskoj i nacional’noj bezopasnosti gosudarstva. Gumanitarnye, social’no-jekonomicheskie i obshhestvennye nauki, 12(1), 162-165. https://doi.org/10.23672/c1758-0305-6989-g

20. Sataeva, L. G., Myrzabaeva, N. A., Shopabaeva A. R. (2019). Sovremennaja sistema zakupok lekarstvennyh sredstv bol’nym social’no znachimymi zabolevanijami v Kazahstane. Psihicheskoe zdorov’e, 2, 13-17. https://doi.org/10.25557/2074-014X.2019.02.13-17

21. Zhusupova, G. K., Skvirskaja, G. P., Esbatyrova, L. M., Bajdullaeva, D. K., Kalieva, Sh. S. (2019). Obzor sistemy lekarstvennogo obespechenija naselenija Kazahstana i ispol’zovanija lekarstvennyh sredstv na ambulatornom urovne. Sovremennye problemy zdravoohranenija i medicinskoj statistiki, 4, 327-345.

22. Aliyeva, N. A., Manap, A. S., & Issabayev, M. M. (2020). Kazakhstan’s pharmaceutical market in the context of global trends. Jekonomicheskaja serija Vestnika ENU im. L.N. Gumileva, 4, 21-35. https://doi.org/10.32523/2079-620X-2020-4-21-35

23. Kul’zhanov, M. K., Zhanturiev, B. M., Nadyrov, P. T. (2019). Rol’ NCJeLS v lekarstvennom obespechenii naselenija Kazahstana. Vestnik Kazahskogo nacional’nogo medicinskogo universiteta, 1, 644-646.

24. Spanov, M. U. (2019). Konkurentosposobnost’ i razvitie farmacevticheskoj promyshlennosti Kazahstana. Jekonomika: strategija i praktika, 14 (3), 69-84.

25. Dathaev, U. M., Shopabaeva, A. R., Erzhanova, R. B. (2019). Analiz dejatel’nosti farmacevticheskih distrib’jutorov Respubliki Kazahstan. Social’naja apteka v zdravoohranenii, 5 (1), 41-48, https://doi.org/10.24959/sphhcj.19.143

26. David, I. Preţul mediu al unei cutii de medicamente s-a dublat în ultimii şapte ani. Ziarul Financiar. 2012; Accessed 26 Jul 2018.

27. Seung-Lai, Yoo., Dae-Jung, Kim., Seung-Mi, Lee., Won-Gu, Kang., Sang-Yoon, Kim., Jong Hyuk, Lee., Dong-Churl, Suh. (2019). Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System. International Journal of Environmental Research and Public Health - Open Access Journal, 16, 288.

28. Habl, C., Schneider, P., Sebesta, R., & Németh, G. (2018). Euripid Collaboration Guidance Principles for External Reference Pricing in Europe. European Journal of Public Health, 28 (4). https://doi.org/10.1093/eurpub/cky212.217

29. LSE Health, Medical Technology Research Group: Survey of key experts on the regulation of medical technology. http://www.lse.ac.uk/lse-health/research/mtrg (2017).

30. Espin, J., Rovira, J., & Olry de Labry, A. (2019). External reference pricing. WHO; Health Action International. [Electronic resource]. URL: http://www.haiweb.org/medicineprices/24072012/ERPfinalMay2011.pdf (date of access: 6.08.2019).

31. Stargardt, T., & Schreyögg, J. (2006). Impact of cross-reference pricing on pharmaceutical prices. manufacturers’ pricing strategies and price regulation. Appl Health Econ Health Policy, 5(4), 235-47.

32. Persson, U., & Jonsson, B. (2016). The end of the international reference pricing system? Appl Health Econ Health Policy, 14(1), 1-8.

33. Espin, J., Rovira, J., Ewen, M., & Laing, R. (2014). Espin, J., Rovira, J., Ewen, M., & Laing, R. (2014). WHO/HAI Project on Medicines Prices and Availability. Review Series on Pharmaceutical Pricing Policies and Interventions. Working Paper 1: External price referencing. Andalusian School of Public Health.

34. Zagidullina, G. N., Omirbaeva, B. S. Analiz chastnyh rashodov na zdravoohranenie v Kazahstane i predlozhenija po ih snizheniju. Analiticheskij obzor dlja formirovanija politiki (Policy Brief), Nur-Sultan: Respublikanskij centr razvitija zdravoohranenija, 2019, P.20.

35. Eatwell, E., & Swierczyna, A. (2019). Emerging voluntary cooperation between European healthcare systems: Are we facing a new future? Medicine Access @ Point of Care. https://doi.org/10.1177/2399202619852317.

36. Kohler, J. C., Mitsakakis, N., Saadat, F., Byng, D., & Martinez, M. G. (2015). Does Pharmaceutical Pricing Transparency Matter? Examining Brazil’s Public Procurement System. Glob Health, 11, 34-015-0118-8.25